A 58-year-old woman from Mumbai undergoes mammography for screening and is found to have a 2 cm irregular mass in the left breast with microcalcifications. Core needle biopsy confirms invasive ductal carcinoma (IDC), grade 2. Sentinel lymph node biopsy shows no metastases. Immunohistochemistry reveals ER+, PR+, HER2 negative. What is the most appropriate next step in management?

Explanation

## Management of Early-Stage, Hormone-Receptor–Positive Breast Cancer **Key Point:** For early-stage, node-negative, hormone-receptor–positive breast cancer, breast-conserving surgery (BCS) with radiation and endocrine therapy is the standard of care and is equivalent to mastectomy in terms of overall survival. ### Rationale for BCS + Radiation + Hormonal Therapy **High-Yield:** The patient has: - **T2, N0, M0** disease (stage IIA) - **ER/PR positive, HER2 negative** (luminal A subtype) - **Grade 2** (intermediate differentiation) This profile is ideal for breast-conserving surgery because: 1. **Tumor size and location**: 2 cm is amenable to BCS with adequate margins. 2. **Nodal status**: Negative sentinel lymph node biopsy indicates no regional spread. 3. **Hormone sensitivity**: ER/PR positivity makes the tumor responsive to tamoxifen or aromatase inhibitors, reducing recurrence risk. 4. **Equivalent outcomes**: BCS + radiation achieves the same locoregional control and overall survival as mastectomy in early-stage disease. ### Treatment Algorithm for Early-Stage Breast Cancer ```mermaid flowchart TD A[Early-stage breast cancer<br/>T1-2, N0, M0]:::outcome --> B{Candidate for BCS?}:::decision B -->|Yes<br/>Adequate margins achievable| C[Breast-conserving surgery]:::action B -->|No<br/>Multicentric, large relative to breast| D[Mastectomy ± reconstruction]:::action C --> E[Radiation therapy to breast]:::action D --> F{Axillary involvement?}:::decision E --> G{ER/PR status?}:::decision F -->|N+| H[Axillary radiation or dissection]:::action G -->|Positive| I[Hormonal therapy<br/>Tamoxifen or AI]:::action G -->|Negative| J{HER2 positive?}:::decision J -->|Yes| K[Trastuzumab ± chemotherapy]:::action J -->|No| L[Consider chemotherapy<br/>based on grade/age]:::action I --> M[Follow-up surveillance]:::outcome ``` **Mnemonic:** **LUMPET** = **L**umpectomy (BCS), **U**ndergo **M**ammography follow-up, **P**athology margins clear, **E**ndocrine therapy, **T**reatment with radiation. **Clinical Pearl:** Hormonal therapy (tamoxifen for premenopausal, aromatase inhibitors for postmenopausal women) is the backbone of treatment for ER+ breast cancer and can reduce recurrence by ~50%. [cite:Robbins 10e Ch 17]